Source: steele/Getty Images

Colitis Reduced by Gut Microbiome-Pomegranate Partnership

Researchers in India and U.S. demonstrate how a pomegranate-derived metabolite can help protect against and reduce symptoms of IBD
The rapid development of NGS-based tests for use in oncology has highlighted this technology’s tremendous potential to improve clinical care and patient outcomes.

Reimbursing NGS Testing

After many years of steady development in DNA sequencing, the scientific community is reaching an exciting threshold in understanding the genetic riddles behind cancerous...

Genomind Restores Drug Information to PGx Reports, But Only for Physicians

Genomind said it has resumed including information about medications in its reports on pharmacogenomic tests, a month after removing it—but only in versions of...

MilliporeSigma and the Broad Institute Agree to Non-Exclusive CRISPR License Framework

MilliporeSigma and the Broad Institute of MIT and Harvard have agreed to offer non-exclusive licenses to CRISPR intellectual property (IP) for use in commercial...
Mopic/Fotolia

Scientists Report Significant Big Data Advance that Integrates Lipidomics and Transcriptomics

Researchers at the Norwich, U.K.-based Genome Analysis Center (TGAC) say they have developed a unique bioinformatics approach for identifying associations between molecules from a...
Using NGS to detect cell-free DNA and other biomarkers could transform cancer care.  [© Photographee.eu/Fotolia.com]

Early Detection: The Real Way to Beat Cancer

More than 40 years after President Nixon declared the War on Cancer in 1971, we are losing that battle. According to the American Cancer...
Billy Boyle

Owlstone Medical to Fund Global Commercialization with $50M Financing

New funding will allow for the global commercialization of the company's Breath Biopsy technology which measures volatile organic compounds
Sourse: NASA

OMICS in Space: NASA Video Seeks to Advance Personalized Medicine on Terra Firma

New video highlights NASA's twins study research.
Qiagen has rolled out an improved version of its Qiagen Clinical Insight (QCI) software that incorporates the AMP/ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. [Source: © Mopic/Fotolia.com]

Qiagen Integrates AMP/ASCO/CAP Variant Guidelines Into QCI-Interpret Solution

Qiagen launches improved version of its QCI-Interpret software incorporating AMP/ASCO/CAP guidelines for interpreting cancer variants
Source: iStock/© AlexRaths

Rosetta Genomics to Acquire PersonalizeDx

Rosetta Genomics said today it has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude, in a purchase that expands the buyer’s...
Scroll Up